Clinical Trials Logo

Weight Loss clinical trials

View clinical trials related to Weight Loss.

Filter by:

NCT ID: NCT04933305 Completed - Obesity Clinical Trials

Microstructure of Ingestive Behavior and Body Weight Loss After Roux-en-Y Gastric Bypass

Drinkometer
Start date: April 1, 2019
Phase:
Study type: Observational

Studies of appetitive behavior in humans after RYGB have produced ambiguous results. It therefore remains unclear whether there are fundamental shifts in the palatability of high-fat and sugary foods after RYGB or simply a decrease in the appetitive drive to ingest them. Moreover, learning processes may play a role as changes in diet selection progress with time in rats after RYGB. However, direct measures of an altered food selection in humans after RYGB are rare and both the durability of the phenomenon as well as the role of experience for changes in food selection remain elusive.

NCT ID: NCT04914819 Completed - Weight Loss Clinical Trials

Postpartum Weight Loss for Women at Elevated Cardiovascular Risk

EMPOWER-Mom
Start date: June 18, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to test the feasibility and effectiveness of a 16-week online behavioral weight loss program compared to usual care to promote weight loss in the postpartum period among women with cardiovascular risk factors. The investigators will also be testing different behavioral strategies to recruit postpartum women to the study, including 2 email recruitment strategies and 2 mailer recruitment strategies, informed by behavioral design.

NCT ID: NCT04910620 Not yet recruiting - Weight Reduction Clinical Trials

The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults

Start date: June 15, 2021
Phase: Phase 4
Study type: Interventional

Obesity is a serious global public health issue. Many reports have showed that the use of appropriate probiotics can bring benefits to the health of the host and promote the balance of gut microbiota. Clinical experimental data show that the supplement of probiotics can help regulate gut function and weight control, and etc. TCI378 (Lactobacillus plantarum TCI378) is a probiotic extracted from Korean kimchi, and TCI507 (Lactobacillus plantarum TCI507) is a probiotic extracted from the oranges peels. These two strains of probiotics have been verified by in vitro experiments to have the effect of hydrolyzing bile salts, inhibition of the production of fat cells. Therefore, we want to evaluate whether the probiotics TCI308 and TCI507 have effects on reduction of body weight.

NCT ID: NCT04907396 Recruiting - Obesity Clinical Trials

International Weight Control Registry

IWCR
Start date: December 10, 2020
Phase:
Study type: Observational [Patient Registry]

The IWCR is a global scientific study aimed at better understanding the opportunities and barriers for reducing the prevalence of obesity by collecting information from people who have experience with weight management in their everyday lives. The investigators seek to gather information on a wide range of weight management experiences, ranging from weight loss and weight loss maintenance to weight gain and inability to lose weight.

NCT ID: NCT04902001 Completed - Pediatric Obesity Clinical Trials

Role of Mechanical Load on Metabolic Exercise Adaptations in Response to Weight Loss in Obese Adolescents: The POWELL Study

POWELL
Start date: August 20, 2021
Phase: N/A
Study type: Interventional

While interdisciplinary weight loss intervention have been shown successful among adolescents with obesity, a weight regain is most of the time observed within the following weeks or months. The aim of the present project will be to better identify the independent role played by both the metabolic and mechanical load and their modification during weight loss, on the energy expenditure and energy metabolism of adolescents with obesity.

NCT ID: NCT04897698 Completed - Overweight Clinical Trials

Probiotics for Weight Loss

Start date: October 16, 2021
Phase: N/A
Study type: Interventional

This study will investigate a compound of probiotics and prebiotics in females and males with overweight with the aim to evaluate the effect on weight and metabolic markers. The design is a three month randomized doubled-blinded, three-armed placebo-controlled trial of probiotics for weight loss. Normal dose (2 capsules á 0.4g per day) doubled dose (4 capsules á 0.4g per day), or placebo. A second, non-blinded, phase with only the compound of probiotics and prebiotics, with tripple dose (6 capsuled á 0.4g per day), will be performed for individuals who had the compound in the first phase.

NCT ID: NCT04893954 Recruiting - Clinical trials for Low Back Pain in Obese Patients After Important Weight Loss

Prospective Study on the Consequences of Weight Loss After Bariatric Surgery on Obese Patients' Spine.

SPINOB
Start date: June 3, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how an important weight loss after bariatric surgery affects obese patients ' spine, and the effects it has on low back pain, sagittal alignment and lipomatosis .

NCT ID: NCT04893772 Completed - Weight Loss Clinical Trials

Meal Timings, Appetite, Mood and Weight Loss in Individuals on a Commercial Intermittent Fasting Programme

DASMA
Start date: June 30, 2021
Phase:
Study type: Observational

Although individuals following commercial intermittent fasting programmes consume meal replacement products during fasting days, further behavioural variables such as time of food consumption, sleep quality and duration, appetite and mood may significantly impact weight loss and intervention success. This project aims to assess behavioural patterns (dietary intake, sleep, meal timing, physical activity), mood and appetite on both fasting and non-fasting days and to investigate whether these are associated with weight loss.

NCT ID: NCT04892030 Completed - Obesity Clinical Trials

Evaluating a Remotely Delivered Plant-Based Behavioral Weight Loss Treatment

Start date: November 25, 2020
Phase: N/A
Study type: Interventional

Many individuals do not achieve clinically significant weight loss following traditional lifestyle modification interventions, potentially because weight loss is dependent upon calorie tracking compliance (to achieve calorie prescriptions), which decreases over time for most. By contrast, non-energy-restricted whole food plant-based diets (WFPBD) have been demonstrated to promote clinically significant weight loss even without calorie prescriptions. The present pilot trial represents the first, to the knowledge of our study team, to empirically test a remotely delivered WFPBD behavioral weight loss intervention for adults with overweight or obesity. Over 12-weeks, participants (N = 21) will follow a non-energy-restricted WFPBD and received nutritional counseling and behavioral weight loss intervention. Participation will occur in two phases (Phase 1: n = 7; Phase 2: n = 14), between which iterative changes to the intervention will be made. Assessments will occur at baseline, mid-treatment, post-treatment, and 3-month follow-up. Data will be analyzed using an intent-to-treat approach. The primary aims of the study will be to assess retention feasibility and acceptability. The secondary aims will be to evaluate the preliminary effectiveness of the intervention on: (1) percent weight loss; (2) dietary intake (i.e., increased intake of low-fat plant-based whole foods and decreased in intake of processed foods and animal products); and (3) waist circumference. The exploratory aims will be to evaluate the preliminary effectiveness of the intervention on physical- and mental health-related quality of life, and to examine potential moderators of treatment success (plant-based diet history, internal disinhibition, social support vs. social sabotage, self-compassion, and psychological flexibility).

NCT ID: NCT04887766 Not yet recruiting - Weight Loss Clinical Trials

Study on GS300 on NAFLD

REVERT
Start date: July 1, 2022
Phase: N/A
Study type: Interventional

To determine the efficacy of GS300 when administered for 24 weeks in patients with Nonalcoholic Fatty Liver Disease (NAFLD).